Showing 1 - 13 results of 13 for search 'Violeta Serra', query time: 0.71s
Refine Results
-
1
Sensitizing HR-proficient cancers to PARP inhibitors by Elgene Lim, Shawn F. Johnson, Matthias Geyer, Violeta Serra, Geoffrey I. Shapiro
Published 2017-11-01
Article -
2
-
3
GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells by Chiara Bellio, Marta Emperador, Pol Castellano, Albert Gris-Oliver, Francesc Canals, Alex Sánchez-Pla, Esther Zamora, Joaquín Arribas, Cristina Saura, Violeta Serra, Josep Tabernero, Bruce A. Littlefield, Josep Villanueva
Published 2022-05-01
Article -
4
Anti‐tumoural activity of the G‐quadruplex ligand pyridostatin against BRCA1/2‐deficient tumours by Florian J Groelly, Manuela Porru, Jutta Zimmer, Hugo Benainous, Yanti De Visser, Anastasiya A Kosova, Serena Di Vito, Violeta Serra, Anderson Ryan, Carlo Leonetti, Alejandra Bruna, Annamaria Biroccio, Madalena Tarsounas
Published 2022-03-01
Article -
5
RAD51 as a biomarker for homologous recombination deficiency in high‐grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test by Claire JH Kramer, Alba Llop‐Guevara, Elisa Yaniz‐Galende, Benedetta Pellegrino, Natalja T terHaar, Andrea Herencia‐Ropero, Nicoletta Campanini, Antonino Musolino, Tjalling Bosse, Alexandra Leary, Violeta Serra, Maaike PG Vreeswijk
Published 2023-11-01
Article -
6
Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models by María Jimena Rodriguez, María Cecilia Perrone, Marina Riggio, Marta Palafox, Valeria Salinas, Andrés Elia, Natali Daiana Salgueiro, Andrea Eugenia Werbach, María Paula Marks, Marcelo A. Kauffman, Luciano Vellón, Violeta Serra, Virginia Novaro
Published 2023-02-01
Article -
7
MiR‐182‐3p targets TRF2 and impairs tumor growth of triple‐negative breast cancer by Roberto Dinami, Luca Pompili, Eleonora Petti, Manuela Porru, Carmen D'Angelo, Serena Di Vito, Angela Rizzo, Virginia Campani, Giuseppe De Rosa, Alejandra Bruna, Violeta Serra, Miguel Mano, Mauro Giacca, Carlo Leonetti, Gennaro Ciliberto, Madalena Tarsounas, Antonella Stoppacciaro, Stefan Schoeftner, Annamaria Biroccio
Published 2023-01-01
Article -
8
Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition by Diar Aziz, Neil Portman, Kristine J. Fernandez, Christine Lee, Sarah Alexandrou, Alba Llop-Guevara, Zoe Phan, Aliza Yong, Ashleigh Wilkinson, C. Marcelo Sergio, Danielle Ferraro, Dariush Etemadmoghadam, David D. Bowtell, kConFab Investigators, Violeta Serra, Paul Waring, Elgene Lim, C. Elizabeth Caldon
Published 2021-08-01
Article -
9
Clinical consequences of BRCA2 hypomorphism by Laia Castells-Roca, Sara Gutiérrez-Enríquez, Sandra Bonache, Massimo Bogliolo, Estela Carrasco, Miriam Aza-Carmona, Gemma Montalban, Núria Muñoz-Subirana, Roser Pujol, Cristina Cruz, Alba Llop-Guevara, María J. Ramírez, Cristina Saura, Adriana Lasa, Violeta Serra, Orland Diez, Judith Balmaña, Jordi Surrallés
Published 2021-09-01
Article -
10
Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers by Jennifer B. Shah, Dana Pueschl, Bradley Wubbenhorst, Mengyao Fan, John Pluta, Kurt D’Andrea, Anna P. Hubert, Jake S. Shilan, Wenting Zhou, Adam A. Kraya, Alba Llop Guevara, Catherine Ruan, Violeta Serra, Judith Balmaña, Michael Feldman, Pat J. Morin, Anupma Nayak, Kara N. Maxwell, Susan M. Domchek, Katherine L. Nathanson
Published 2022-11-01
Article -
11
Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple‐negative breast cancer by Laura Pascual‐Reguant, Queralt Serra‐Camprubí, Debayan Datta, Damiano Cianferoni, Savvas Kourtis, Antoni Gañez‐Zapater, Chiara Cannatá, Lorena Espinar, Jessica Querol, Laura García‐López, Sara Musa‐Afaneh, Maria Guirola, Anestis Gkanogiannis, Andrea Miró Canturri, Marta Guzman, Olga Rodríguez, Andrea Herencia‐Ropero, Joaquin Arribas, Violeta Serra, Luis Serrano, Tian V Tian, Sandra Peiró, Sara Sdelci
Published 2023-12-01
Article -
12
Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors by Álvaro Lahiguera, Petra Hyroššová, Agnès Figueras, Diana Garzón, Roger Moreno, Vanessa Soto‐Cerrato, Iain McNeish, Violeta Serra, Conxi Lazaro, Pilar Barretina, Joan Brunet, Javier Menéndez, Xavier Matias‐Guiu, August Vidal, Alberto Villanueva, Barbie Taylor‐Harding, Hisashi Tanaka, Sandra Orsulic, Alexandra Junza, Oscar Yanes, Cristina Muñoz‐Pinedo, Luís Palomero, Miquel Àngel Pujana, José Carlos Perales, Francesc Viñals
Published 2020-06-01
Article -
13
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation by Marta Castroviejo‐Bermejo, Cristina Cruz, Alba Llop‐Guevara, Sara Gutiérrez‐Enríquez, Mandy Ducy, Yasir Hussein Ibrahim, Albert Gris‐Oliver, Benedetta Pellegrino, Alejandra Bruna, Marta Guzmán, Olga Rodríguez, Judit Grueso, Sandra Bonache, Alejandro Moles‐Fernández, Guillermo Villacampa, Cristina Viaplana, Patricia Gómez, Maria Vidal, Vicente Peg, Xavier Serres‐Créixams, Graham Dellaire, Jacques Simard, Paolo Nuciforo, Isabel T Rubio, Rodrigo Dienstmann, J Carl Barrett, Carlos Caldas, José Baselga, Cristina Saura, Javier Cortés, Olivier Déas, Jos Jonkers, Jean‐Yves Masson, Stefano Cairo, Jean‐Gabriel Judde, Mark J O'Connor, Orland Díez, Judith Balmaña, Violeta Serra
Published 2018-12-01
Article